Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000 (R) System

作者：Hermida Cadahia Esperanza F; Carlos Tutor J

来源：Scandinavian Journal of Clinical & Laboratory Investigation, 2012, 72(2): 180-183.

DOI：10.3109/00365513.2011.646300

• Everolimus
• sirolimus
• microparticle enzyme immunoassay
• chemiluminescence magnetic microparticle immunoassay
• Architect (R) system

Background. There is significant immunoassay cross-reactivity between everolimus and sirolimus, and their routine determination using a common method may reduce the reagent costs. Methods. In 122 blood samples from kidney (n = 30) and liver (n = 92) transplant recipients, everolimus concentrations were determined using the Abbott IMx (R) microparticle enzyme immunoassay (MEIA) as previously described, and the Abbott sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000 (R) system. Results. A high correlation coefficient (r = 0.981, p < 0.001) and a linear regression MEIA = 0.73CMIA + 0.55, with an acceptable standard error of the estimate (ma68 = 0.32 ng/mL), were obtained, indicating the transferability of the results produced by both immunoassays. Conclusions. The newly-developed sirolimus CMIA assay on the Architect (R) platform may be a valid alternative to other immunoassays for the routine therapeutic monitoring of everolimus.

• 出版日期2012-4